Mymetics Corp (MYMX)

[Work Harder]

Lukas Fierz

- The company Vaxart (NASDAQ: VXRT) from San Francisco has been developing oral vaccinations against the diarrhea-causing norovirus and against the uterine cancer-causing papillomavirus for a long time.

Together with Janssen (subsidiary of Johnson & Johnson) she is developing an oral flu vaccination, which in a phase II study gave better results than an established injection vaccination - if confirmed by a phase III study, that would be an absolute sensation.

Vaxart's Covid vaccine gave good protection in animal studies, and a Phase I human trial produced cellular immunity and local Ig-A antibodies, but no IgG antibodies in serum, causing the share price to fall.

This seems unjustified because one in sixteen Covid healed people also has no serum antibodies , and because animal experiments have shown that cellular immunity protects against low levels of antibodies .

And if that vaccination prevented the virus from reaching the bloodstream, the lack of serum antibodies wouldn't be a disadvantage. Only clinical trials can clarify this.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163254853

Thanks to the poster

Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine
July 9, 2019 at 8:00 AM EDT

https://investors.vaxart.com/news-releases/news-release-details/vaxart-enters-research-collaboration-janssen-evaluate-oral